Tinostamustine Enters Phase 1/2 Trial to Treat Ovarian Cancer, Other Solid Tumors

Tinostamustine Enters Phase 1/2 Trial to Treat Ovarian Cancer, Other Solid Tumors
The investigational medicine tinostamustine (EDO-S101), developed by Mundipharma EDO GmbH, is now being tested in patients with advanced solid tumors, including ovarian cancer, in a first-in-human Phase 1/2 clinical trial. The trial will assess the safety, tolerability, and effectiveness of the new treatment in participants recruited at Stanford University, Cedars Sinai Medical Center in Los Angeles, California, and The Mayo Clinic in Scottsdale, Arizona. "Following the initial Phase 1 study in hematological malignancies [NCT02576496], I am delighted that EDO is now embarking on a further clinical trial in solid tumors,” Thomas Mehrling, MD, PhD, said in a press release. Mehrling is CEO of EDO. Tinostamustine is an alkylating deacetylase inhibiting molecule that binds to the genetic content of cancer cells, promoting DNA damage and, at the same time, counteracting any attempts of DNA damage repair by the cancer cells. Preclinical studies have suggested that this mode of action has the potential to overcome resistance to therapy, promoting cancer cell death more effectively than traditional DNA-damaging therapies . The investigatational drug has demonstrated potential to effectively target small cell lung cancer (SCLC) cells, soft tissue sarcoma (STS) or non-KIT gastrointestinal str
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *